甲状腺癌的分子靶向治疗进展.pdfVIP

肿瘤2011 年7 月第31 卷第7 期　Tumor Vol.31, J uly 2011　　 671 DOI:10.3781/j .issn.1000-7431.2011.07.019 Copyright© 2011 by TUM OR Review 综述 · 甲状腺癌的分子靶 向治疗进展 冀　叶，马　静，李晓江 昆明医学院第三附属医院 （云南省肿瘤医院）头颈外科，云南省头颈肿瘤研究中心，昆明　650118 [ 摘要 ]　 甲状腺癌的治疗方法主要以手术为主，但对于转移性的、侵袭性的和晚期的甲状腺癌患者来说，手术效 果有限，而且碘放射治疗和化疗对这些恶性程度较高的肿瘤治疗效果往往不太理想，因此分子靶向治疗的出现则 为这些患者带来了新的希望。本文将从甲状腺癌发病的分子机制，分子靶向治疗药物的作用机制、治疗效果和不 良反应等方面作一综述。 [ 关键词 ]　甲状腺肿瘤；蛋白激酶抑制剂类；抗肿瘤联合化疗方案 [中图分类号]　R736.1 [文献标志码] A [文章编号]　1000-7431(2011)07-0671-04 Progress in molecular targeted therapy for thyroid carcinoma JI Ye, MA Jing, LI Xiao-jiang Department of Head and Neck Surgey, Third Affiliated Hospital of Kunming Medical University, Head and Neck Tumor Research Center of Yunnan Province, Kunming 650118, China [A BSTRACT]　The treatment for thyroid cancer is mainly based on surgery. However, for the patients with metastatic, invasive and advanced thyroid cancer, the therapeutic efficacy of surgical operation is limited. Meanwhile, the radioactive iodine therapy and chemotherapy for high-grade thyroid cancer exert no substantial effects. The development of molecular targeted therapy brings new hopes for these patients. This article reviews the molecular pathogenesis of thyroid cancer, the mechanism of action of molecular targeted drugs and the therapeutic effects and adverse reactions of these targeted drugs. [KEY WORDS]　Thyroid neoplasms; Protein kinase inhibitors; Antineoplastic combined chemotherapy protocols [Tumor, 2011, 31(7): 671-674] 甲状腺癌的发病率在恶性肿瘤中约占1% ，是内分泌系 kinase ，PI3K ）和AKT 1，核转录因子PPAR γ1 等多个 统中最常见的肿瘤之一，也是内分泌系统肿瘤引起死亡的 位点[3] 。RET/PTC-RA S-RAF-MEK/ERK- 丝裂原活化 主要原因[1] 。统计研究表明，2010 年在美国，有33 930 例 蛋白激酶 （